Definium's DT120 ODT Achieves Significant Anxiety Improvement In Phase 3 Trial; Stock Up

Oppenheimer increased its price target for Definium Therapeutics (DFTX) to $75 from $70, maintaining an Outperform rating. The firm cited positive Phase 3 trial results for DT120, which it believes support the company's potential to improve treatment for GAD patients. Oppenheimer updated its model to reflect increased optimism.

Definium Therapeutics (DFTX) reported that its LSD-based treatment reduced anxiety symptoms by 9.8 points on a 56-point scale, compared to 4.7 for placebo. The company's shares, already up 190% this year, rose further on the news.

Definium Therapeutics (DFTX) stock surged 20.7% in pre-market trading after its Phase 3 trial of DT120 ODT for generalized anxiety disorder met its primary endpoint. The company has also received FDA Breakthrough Therapy designation for DT120 in major depressive disorder. Analysts had previously assigned Buy or Strong Buy ratings, with price targets above current levels. The stock is nearing its 52-week high of $49.70, up from a low of $8.77.

Definium Therapeutics (DFTX) shares rose 20% after reporting positive Phase 3 trial results for DT120 ODT in treating generalized anxiety disorder. The study met primary and secondary endpoints, showing a 5.1-point reduction in anxiety scores. The drug was well-tolerated, with a safety profile consistent with prior trials. The company plans to file for FDA approval in 2027.

Definium Therapeutics (DFTX) will host a webcast on September 14, 2026, to discuss topline results from its Phase 3 Panorama study of DT120 ODT for generalized anxiety disorder. The study enrolled 245 participants across 32 centers, with primary endpoints focused on changes in HAM-A and CGI-S scores. Definium Therapeutics is a Nasdaq-listed biopharmaceutical company developing psychiatric and neurological disorder treatments.

Definium Therapeutics (DFTX) reported positive Phase 3 results for DT120 ODT in treating generalized anxiety disorder, meeting primary and secondary endpoints. Shares have surged 12.88% in 7 days and 121.27% in 90 days, with a 1-year return of 391.80%. Analysts estimate revenue of $320.2M by July 2029 and a 1.7% profit margin, suggesting a 22.3% undervaluation at $46.18 vs. a $59.47 fair value.